Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
← catalyst calendarNCT05065216 · readout ≤ 134 d
Sponsored by DiaMedica Therapeutics Inc (industry) · DMAC — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
728estimated
Sites
66
Countries
Belgium, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-07 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Stroke
- Ischemic Stroke
- Stroke
Interventions
- Drug: Recombinant human tissue kallikrein — also filed as DM199
- Other: Placebo for DM199 Solution for Injection
Primary outcome
what the primary-completion date above is the date OFStroke Recovery
measured Day 90
Permalink · DMAC's whole pipeline · Catalyst calendar · Every registered study · What changed